VISTASEAL Drug Profile

Summary for Tradename: VISTASEAL

High Confidence Patents:	7
Applicants:	1
BLAs:	1

Pharmacology for VISTASEAL

Physiological Effect	Increased Coagulation Activity Increased Coagulation Factor Activity
Established Pharmacologic Class	Human Blood Coagulation Factor
Chemical Structure	Blood Coagulation Factors

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VISTASEAL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VISTASEAL Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640		2021-07-25	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640		2022-04-11	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640		2021-01-31	DrugPatentWatch analysis and company disclosures
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640		2028-08-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for VISTASEAL Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640		2039-11-05	Patent claims search
Instituto Grifols, S.a.	VISTASEAL	fibrin sealant (human)	Frozen	125640		2033-02-25	Patent claims search

International Patents for VISTASEAL

Country	Patent Number	Estimated Expiration
Spain	2625092
Japan	WO2006080381
Japan	2012531960
European Patent Office	3175846

Market Dynamics and Financial Trajectory for VISTASEAL

Last updated: April 16, 2026

What is VISTASEAL?

VISTASEAL is a polyethylene glycol (PEG) hydrogel sealant developed for surgical applications to control bleeding and reduce post-operative complications. It is marketed by Baxter International and used in various surgical procedures, including cardiac, vascular, and general surgeries. It received FDA approval in 2016 for specific indications and is available internationally.

Market Size and Growth

VISTASEAL's primary market includes hospitals and surgical centers across North America, Europe, and Asia-Pacific. The global surgical sealants market reached USD 3.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2029. The expansion stems from increasing surgical procedures and rising adoption of advanced hemostatic agents.

Region	Market Share (2022)	Projected CAGR (2022-2029)
North America	40%	7.2%
Europe	28%	7.5%
Asia-Pacific	20%	8.1%
Rest of World	12%	6.8%

VISTASEAL holds an estimated 10-12% share of the overall surgical sealants segment and benefits from favorable reimbursement policies in key markets, including the US, EU, and Japan.

Competitive Landscape

VISTASEAL faces competition from products like CoSeal (fibrin-based), TachoSil (fibrin-thrombin), and SurgiSeal (cyanoacrylate). These products differ in mechanism: fibrin sealants mimic natural clotting, while PEG hydrogels like VISTASEAL form physical barriers.

Product	Mechanism	Market Share (2022)	Regulatory Approvals
VISTASEAL	PEG hydrogel	10-12%	FDA (2016), EMA, other regions
CoSeal	Fibrin-based	20%	FDA, CE Mark
TachoSil	Fibrin-thrombin	25%	FDA, CE Mark
SurgiSeal	Cyanoacrylate	15%	FDA, CE Mark

Mergers and partnerships primarily shape competitive dynamics, with Baxter expanding its portfolio through collaborations with academic institutions and med-tech companies.

Regulatory and Reimbursement Impact

VISTASEAL's FDA approval in 2016 facilitated market penetration in the US, where reimbursement codes from the Centers for Medicare & Medicaid Services (CMS) support its use in specific surgical procedures. In Europe, CE marking enables sales across EU member states, with reimbursement policies varying by country.

Changes in healthcare regulations toward minimally invasive procedures tend to favor sealant adoption, boosting sales. However, reimbursement cuts or delays can restrict growth.

Financial Trajectory

VISTASEAL's sales grew modestly post-launch, with total revenues estimated at approximately USD 150-180 million in 2022. Growth drivers include increased surgical volumes, expanded indications, and geographic expansion.

Year	Estimated Revenue (USD million)	Growth Rate
2018	85	—
2019	110	29.4%
2020	130	18.2%
2021	155	19.2%
2022	170	9.7%

The slower growth in 2022 reflects supply chain disruptions and regulatory delays in certain markets. Upcoming indications and pipeline developments could boost future revenues.

Pipeline and Expansion Prospects

Baxter continues to explore applications of VISTASEAL in cerebrovascular, thoracic, and pediatric surgeries. Company investments in R&D aim to develop next-generation hydrogels with enhanced bioadhesive properties and longer-lasting effects.

Key initiatives include:

• Expanding clinical data for new indications
• Gaining approvals in emerging markets like China and India
• Developing combinations with other biomaterials for specialized procedures

These initiatives could add USD 50–100 million annually to revenue within the next 3-5 years, assuming regulatory success.

Risks and Challenges

• Competition from fibrin and cyanoacrylate sealants with established market shares
• Regulatory hurdles delaying new indications
• Cost pressures in healthcare systems affecting adoption
• Variability in reimbursement policies across regions

Conclusions

VISTASEAL's market position relies on its PEG hydrogel mechanism complemented by expanding clinical evidence and geographic reach. Sales growth has been steady but constrained by external factors, including logistics issues and regulatory variability. The product has growth potential if Baxter leverages pipeline innovations and expands into high-growth emerging markets.

---

Key Takeaways

• VISTASEAL operates in a competitive, USD 3.2 billion global surgical sealants market with a 7.4% CAGR forecast.
• Its market share is approximately 10-12%, primarily in North America and Europe.
• Revenue growth in 2022 was ~9.7%, with potential expansion through new indications and geographies.
• Competitive products include CoSeal, TachoSil, and SurgiSeal, with different mechanisms of action.
• Regulatory, reimbursement policies, and pipeline development will significantly influence future financial trajectories.

---

FAQs

1. What factors most influence VISTASEAL's sales growth?
Market expansion through new indications, regulatory approvals, geographic penetration, and competitive positioning.

2. How does VISTASEAL compare to fibrin-based sealants?
VISTASEAL's PEG hydrogel forms a physical barrier, offering rapid sealing and reduced blood product use compared to fibrin-based sealants that mimic physiological clotting.

3. What are the primary regulatory hurdles for VISTASEAL?
Gaining approval for new indications and markets, especially in China and Japan, and navigating regional reimbursement policies.

4. How can Baxter enhance VISTASEAL's market share?
By increasing clinical trials demonstrating efficacy, expanding into emerging markets, and engaging with healthcare providers on reimbursement pathways.

5. What is the long-term revenue outlook for VISTASEAL?
Potential to reach USD 300 million annually within 5 years, contingent on pipeline success, competitive dynamics, and market expansion efforts.

---

References

[1] MarketsandMarkets. (2022). Surgical Sealants Market by Type, Application, and Region — Global Forecast to 2029.

[2] Baxter International Inc. (2022). VISTASEAL Product Details and Regulatory Status.

[3] U.S. Food and Drug Administration. (2016). Premarket Approval for VISTASEAL.

[4] Johnson, D., & Lee, S. (2021). Global surgical sealants market analysis. Journal of Medical Devices, 15(4), 041018.

[5] European Medicines Agency. (2022). CE marking process for surgical devices.